Vertex Revenue

VRTX
 Stock
  

USD 317.60  3.77  1.17%   

Vertex Pharmaceuticals fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Vertex Pharmaceuticals Deferred Revenue is fairly stable at the moment as compared to the past year. Vertex Pharmaceuticals reported Deferred Revenue of 14.53 Million in 2021. Cost of Revenue is likely to rise to about 204.4 M in 2022, whereas Revenue to Assets are likely to drop 0.50 in 2022.

Vertex Revenue Analysis

Vertex Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Vertex Pharmaceuticals Revenues

8.17 Billion

Revenue 
 = 
Money Received 
Discounts and Returns 
More About Revenue | All Equity Analysis

Current Vertex Pharmaceuticals Revenue

    
  7.57 B  
Most of Vertex Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Vertex Revenue Driver Correlations

Understanding the fundamental principles of building solid financial models for Vertex Pharmaceuticals is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Revenue. Since Vertex Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vertex Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vertex Pharmaceuticals' interrelated accounts and indicators.

Vertex Revenue Historical Pattern

Today, most investors in Vertex Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vertex Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vertex Pharmaceuticals revenue as a starting point in their analysis.
   Vertex Pharmaceuticals Revenue   
Share
       Timeline  
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Compare to competition

Vertex Deferred Revenue

Deferred Revenue

14.91 Million

Vertex Pharmaceuticals Deferred Revenue is fairly stable at the moment as compared to the past year. Vertex Pharmaceuticals reported Deferred Revenue of 14.53 Million in 2021
Based on the latest financial disclosure, Vertex Pharmaceuticals reported 7.57 B of revenue. This indicator is about the same for the Biotechnology average (which is currently at 7.63 B) sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is 19.72% higher than that of the company.

Vertex Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics of similar companies.
Vertex Pharmaceuticals is currently under evaluation in revenue category among related companies.

Vertex Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Vertex Pharmaceuticals from analyzing Vertex Pharmaceuticals' financial statements. These drivers represent accounts that assess Vertex Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vertex Pharmaceuticals' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee114.56 K838.76 K392.27 K795.36 K600.54 K647.95 K
Revenue Per Employee1.08 M1.22 M1.39 M1.82 M1.94 M2.1 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA103.26 M706.76 M1.5 B3.26 B2.91 B3.14 B

Vertex Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vertex Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceuticals' managers, analysts, and investors.
Environment Score
Governance Score
Social Score

Vertex Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Vertex Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vertex Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vertex Pharmaceuticals' value.
Security TypeSharesValue
Zwj Investment Counsel IncCommon Shares1.9 K445 K
Zwj Investment Counsel IncCommon Shares1.9 K409 K
Zweigdimenna Associates LlcCommon Shares54.1 K11.6 M
Zweigdimenna Associates LlcCommon Shares151.2 K19 M
Zweigdimenna Associates LlcCommon Shares162.2 K19.3 M
Zweigdimenna Associates LlcCommon Shares98.8 K7.9 M
Zurich Insurance Group LtdCommon Shares46.9 K7.9 M

Vertex Fundamentals

About Vertex Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Deferred Revenue14.5 M14.9 M
Cost of Revenue189.4 M204.4 M
Revenues7.6 B8.2 B
Revenue to Assets 0.56  0.50 
Revenue Per Employee1.9 M2.1 M

Vertex Pharmaceuticals Investors Sentiment

The influence of Vertex Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Vertex. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Vertex Pharmaceuticals' public news can be used to forecast risks associated with investment in Vertex. The trend in average sentiment can be used to explain how an investor holding Vertex can time the market purely based on public headlines and social activities around Vertex Pharmaceuticals. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Vertex Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Vertex Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Vertex Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Vertex Pharmaceuticals.

Vertex Pharmaceuticals Implied Volatility

    
  17.14  
Vertex Pharmaceuticals' implied volatility exposes the market's sentiment of Vertex Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Vertex Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Vertex Pharmaceuticals stock will not fluctuate a lot when Vertex Pharmaceuticals' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vertex Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vertex Pharmaceuticals' short interest history, or implied volatility extrapolated from Vertex Pharmaceuticals options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Also, please take a look at Vertex Pharmaceuticals Piotroski F Score and Vertex Pharmaceuticals Altman Z Score analysis. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for analysis

When running Vertex Pharmaceuticals price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.095
Market Capitalization
82.5 B
Quarterly Revenue Growth YOY
0.18
Return On Assets
0.14
Return On Equity
0.29
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Vertex Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.